Chromatography of functionalized liposomes and their components.

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• Cancer chemotherapy often lacks specificity, leading to systemic toxicity.
• Prodrug strategies can improve drug delivery and efficacy.
• Liposomes offer a versatile platform for targeted drug delivery.

Purpose of the Study:

• To develop a targeted drug delivery system for cancer chemotherapy.
• To create liposomes carrying an antitumour prodrug conjugated with targeting antibodies.
• To evaluate the selective binding of these liposome-antibody complexes to cancer cells.

Main Methods:

• Acylation of 1-beta-D-arabinofuranosylcytosine (ara C) with oleic acid anhydride to form N4-oleoyl-ara C prodrug.
• Incorporation of the lipophilic prodrug and a biotin derivative into unilamellar liposomes using detergent dialysis.
• Complexation of biotinylated liposomes with avidin, followed by removal of unreacted avidin via chromatography.
• Coupling of the prodrug-liposome-avidin complex to biotinylated monoclonal antibodies.
• Removal of unreacted antibodies using chromatography.

Main Results:

• Successfully synthesized a lipophilic prodrug, N4-oleoyl-ara C.
• Created biotinylated prodrug-loaded liposomes.
• Formed stable prodrug-liposome-avidin-antibody complexes.
• Demonstrated selective binding of the complexes to target cells in vitro.

Conclusions:

• The developed liposome-antibody complexes show selective binding to target cells, indicating potential for specific cancer chemotherapy.
• This targeted delivery approach holds promise for reducing side effects and improving therapeutic outcomes in cancer treatment.